Introduction
============

Alzheimer\'s disease (AD) is the most common form of dementia, representing between 50--75% of all cases.[@cit1] In 2017, an estimated 50 million people worldwide suffered from dementia, and this number is projected to grow sharply due to increased life expectancy.[@cit2] The lack of effective treatment strategies for AD, coupled with increased incidence, has stimulated extensive research efforts in this important field.[@cit3]

Clinical diagnosis of AD is currently based on progressive loss of memory and impairment in cognition,[@cit4] with final diagnosis requiring post-mortem examination of the brain to determine the severity of two neuropathological hallmarks; amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs). It is still unclear whether Aβ-plaques, NFTs, or both, are a cause or an effect of the neurodegeneration in AD.[@cit5] NFTs are intracellular aggregates of oxidatively-modified and hyperphosphorylated microtubule-associated protein tau,[@cit6] while Aβ plaques are extracellular and contain the Aβ peptide as the major constituent. The Aβ peptide is a product of the amyloid precursor protein (APP), and a series of cleavage events by α-, β-, γ-secretases,[@cit7] afford the Aβ peptide as predominantly Aβ~1--40~ or Aβ~1--42~ (a 40- or 42-residue peptide).[@cit8] In addition, truncation at the N-terminus results in Aβ~3(p)--*n*~, Aβ~4--*n*~, and Aβ~11(p)--*n*~ (where p refers to pyroglutamate) peptides that are also significant components of amyloid deposits.[@cit9] Aβ can be found in three general forms in the brain: membrane associated, aggregated, and soluble. Most of Aβ is membrane-associated in healthy individuals, but in individuals with AD the aggregated and soluble fractions increase considerably.[@cit8],[@cit10]

Early neuronal and pathological changes show indications of oxidative damage, indicating oxidative stress is involved in AD.[@cit11] The cause of oxidative stress in AD has been attributed to a number of factors, including impaired cellular energy metabolism and/or Fenton-type processes involving redox-active metal-ions (Fe, Cu), and metal-containing aggregates.[@cit12] Metal-ions, such as Zn, Cu and Fe, are essential for healthy organisms and brain function, and are tightly regulated under normal circumstances.[@cit13] However, a change in metal-ion homeostasis in the brain has been associated with protein aggregation, and the generation of reactive oxygen species (ROS) in neurodegenerative diseases such as AD.[@cit14] Metal-ions are present in increased concentrations in Aβ plaques in comparison to normal brain tissue, with concentrations of *ca.* 0.4 mM for Cu, 1 mM for Zn, and 0.9 mM for Fe.[@cit13a],[@cit13b],[@cit15] Metal-ion binding can modify the aggregation pattern of Aβ, disrupt normal metalloenzyme activity, and facilitate the production of ROS.[@cit10b],[@cit14a],[@cit14c],[@cit16] Recent studies have shown that the Aβ--Cu([ii]{.smallcaps}) complex exhibits detrimental catalytic ROS generation, particularly so in the presence of cholesterol and vitamin C, and is able to reduce O~2~ generating the superoxide anion (O~2~˙^--^), hydrogen peroxide (H~2~O~2~), and hydroxyl radical (·OH).[@cit17]

As a result of the possible role of metal-ion dyshomeostasis in AD, the development of multifunctional metal binding molecules as therapeutics has been actively explored.[@cit18] We, and others, have developed metal-binding agents with additional properties such as radical scavenging, peptide binding and aggregation inhibition, and acetylcholine esterase (AChE) activity.[@cit19] In addition, a number of groups have explored the use of discrete metal complexes for the diagnosis and treatment of AD.[@cit20] In terms of therapeutics, Pt,[@cit21] Ru,[@cit22] Ir,[@cit23] Co,[@cit10b],[@cit24] Re,[@cit25] Rh,[@cit26] Mn,[@cit27] and V[@cit28] complexes have been investigated for their ability to modify the aggregation of the Aβ peptide, and certain compounds have shown promising results in disease models. For example, an orally-available Pt([iv]{.smallcaps}) complex ([Scheme 1](#sch1){ref-type="fig"}) was shown to cross the blood--brain barrier (BBB), reduce plaque burden, and reduce Aβ peptide levels in a APP/Ps1 mouse model.[@cit29] Therefore, a metal complex that can bind to the Aβ peptide, modulate aggregation, and reduce ROS production is a promising therapeutic for AD.

![Structures of Pt([iv]{.smallcaps}) complex, and Fe([iii]{.smallcaps}) corrole (**FeL1**) complex.](c8sc04660c-s1){#sch1}

Corrole ligands are known to bind to metal ions, such as Al, Cu, Fe, Ga, and Au, and the corresponding metal complexes display outstandingly high hydrolytic stability.[@cit30] The iron([iii]{.smallcaps}) complex (**FeL1**, [Scheme 1](#sch1){ref-type="fig"}) displays excellent catalase activity,[@cit31] superoxide dismutase (SOD) activity,[@cit30a] and catalytic activity for the decomposition of peroxynitrite (PN, ONOO^--^).[@cit30d],[@cit32] Additionally, **FeL1** binds to and protects the cholesterol-carrying lipoproteins from oxidative stress; and oral administration of **FeL1** to a mouse model of atherosclerosis leads to a decrease in atherosclerotic lesions.[@cit30c],[@cit33] We were thus interested to investigate the interaction of **FeL1** with the Aβ peptide, and how this would modulate peptide aggregation and ROS generation. Strong inspiration came from reports by Dey *et al.*, who have shown that heme binds to the Aβ peptide, that one of the three histidine residues (His^6^) of Aβ is ligated to the heme\'s iron, and that the heme-Aβ adduct induces ROS formation.[@cit17a],[@cit34] Furthermore, a study that focused on the uptake of iron complexes by macrophages, which are a major source of ROS, revealed that heme is cytotoxic while **FeL1** is cytoprotective.[@cit35] Additionally, **FeL1** was reported to have low cytotoxic activity while maintaining cell cycle distribution similar to untreated cancer cells.[@cit36] We report the interaction of **FeL1** with the Aβ peptide, how it affects peptide aggregation, and the radical scavenging ability of the **FeL1**--Aβ adduct, in both the presence and absence of Cu([ii]{.smallcaps}) ions.

Results and discussion
======================

Binding of Aβ His residues to **FeL1**
--------------------------------------

The Fe([iii]{.smallcaps}) complex of the amphipolar 2,17-bis-sulfonato-5,10,15-tris(pentafluorophenyl)corrole (**FeL1**) has very strong affinity to human serum albumin (HSA) and lipoproteins, which is in part due to binding of histidine (His) residues to the metal ion.[@cit30c],[@cit37] The His ligation causes a shift in the Soret band of **FeL1** from 390 to 410 nm, as well as the formation of a new band at 620 nm, and the intensity of the latter band is associated with the binding of either one or two axial His residues.[@cit30c],[@cit31],[@cit37] There are three Aβ His residues (His^6^, His^13^, and His^14^) and they play an important role in metal-ion binding ([Scheme 2](#sch2){ref-type="fig"}), with dissociation constants (*K*~d~) of ∼10^--10^ M for Cu([ii]{.smallcaps}) and ∼10^--5^ M for Zn([ii]{.smallcaps}).[@cit10b],[@cit14a],[@cit38] In addition, Aβ His residues have been reported to bind to discrete metal complexes such as heme,[@cit34a] Ru complexes,[@cit22a],[@cit23a],[@cit39] and Co complexes.[@cit10b],[@cit24] In addition to His binding, residues Asp^1^, Tyr^10^, and Glu^11^ play a role in the coordination of Aβ to Cu([ii]{.smallcaps}) and Zn([ii]{.smallcaps}).[@cit40]

![Representation of Component I (I~a~, I~b~, I~c~) and Component II, the two major pH-dependent Aβ--Cu([ii]{.smallcaps}) binding modes (modified from Borghesani *et al.*, 2018).[@cit9c]](c8sc04660c-s2){#sch2}

Prior to investigating the interaction(s) of **FeL1** with the Aβ peptide by UV-Vis spectroscopy, its binding to 1-methylimidazole (1-MeIm) was examined as to determine the spectral features and binding affinity associated with exogenous imidazole as the axial ligand. Gradual addition of up to 150 equiv. of 1-MeIm led to a shift in the near UV (Soret) band, a decrease in the band at 533 nm, and the formation of a new band at 620 nm ([Fig. 1](#fig1){ref-type="fig"}). The spectral changes matched those for histidine binding (Fig. S1[†](#fn1){ref-type="fn"}),[@cit30c] however in both cases a large excess of ligand is required (150 and 700 equiv. respectively) to observe spectral endpoints. A variable pH UV-Vis titration (Fig. S2[†](#fn1){ref-type="fn"}), at a concentration ratio of 1 : 2 **FeL1** : 1-MeIm, together with subsequent data fitting using Hypspec and HySS,[@cit41],[@cit45] provides binding constants of log M(1-MeIm) = 5.81 ± 0.01 (where M = **FeL1**) and a much smaller log M(1-MeIm)~2~ = 2.57 ± 0.02. Our results are in accord with the higher stability of 5-coordinate mono-axial ligated Fe([iii]{.smallcaps}) corroles in comparison to 6-coordinate bis-axial ligated Fe([iii]{.smallcaps}) corroles,[@cit42] which is opposite to that reported for Fe([iii]{.smallcaps}) porphyrins.[@cit43] The main reason for this difference is that upon bis-axial ligation Fe([iii]{.smallcaps}) porphyrins gain more crystal field stabilization energy (CFSE) as they transform from high spin (HS) to low spin (LS), while Fe([iii]{.smallcaps}) corroles only transform from intermediate spin (IS) to LS.[@cit42b],[@cit42c]

![UV-Vis spectra of 1-MeIm additions to **FeL1** (30 μM, black) in PBS buffer (0.01 M, pH 7.4). Grey lines represent additions of 5 equiv. of 1-MeIm up to 50 equiv. (red) with a maximum of absorption at 620 nm for 150 equiv. shown in green.](c8sc04660c-f1){#fig1}

The studies with 1-MeIm provided critical information for examining the interaction of **FeL1** with the full length Aβ~1--42~ and two truncated peptides: Aβ~1--16~ that contains the metal binding N-terminus (His^6^, His^13^, His^14^), and Aβ~17--40~ with the hydrophobic portion of the peptide lacking any His. Addition of Aβ~17--40~ to **FeL1** did not induce any significant spectral changes, while even a single equivalent of either Aβ~1--42~ or Aβ~1--16~ led to a red shift and intensity-increase of the Soret band, accompanied by the appearance of a *λ*~max~ = 620 nm band ([Fig. 2](#fig2){ref-type="fig"}). While this experiment clearly proves the importance of His--Fe binding, the comparison of [Fig. 2](#fig2){ref-type="fig"} and [1](#fig1){ref-type="fig"} exposes major differences. Importantly, the binding of the protein-provided histidine must be much stronger than that of 1-MeIm as full spectra changes are achieved with 1 *vs.* \>100 equivalents, respectively. In the former case, the observed spectral changes occur immediately upon mixing, with no further spectral changes apparent after monitoring for 1 h, and addition of excess Aβ~1--16~ (up to 16 equivalents, Fig. S3[†](#fn1){ref-type="fn"}) did not induce further spectral changes. The last result is also highly relevant to the other spectral difference: while the 533 nm band disappears in the presence of a large excess of 1-MeIm ([Fig. 1](#fig1){ref-type="fig"}), the bands at 533 and 620 nm remain of essentially equal intensity starting from a 1 : 1 ([Fig. 2](#fig2){ref-type="fig"}) to a 1 : 16 (Fig. S3[†](#fn1){ref-type="fn"}) ratio of **FeL1** : Aβ~1--16~. Taken together, the results show that **FeL1** and Aβ form a 1 : 1 adduct that relies on only one of the His residues in Aβ. The other two His residues are either too far away to approach the metal center and/or are unable to bind due to steric interference. Previous reports agree with our findings in that axial ligand binding to Fe([iii]{.smallcaps}) corroles shows that the 5-coordinate species is stabilized in comparison to the 6-coordinate bis-axial ligated species.[@cit42a],[@cit42b],[@cit44]

![UV-Vis spectra of **FeL1** (30 μM, black) in the presence of 1 equiv. of Aβ~17--40~ (red), Aβ~1--16~ (green) and Aβ~1--42~ (blue) in PBS buffer (0.01 M, pH 7.4).](c8sc04660c-f2){#fig2}

The stability of the 1 : 1 **FeL1** : Aβ~1--16~ adduct was determined *via* a variable pH titration ([Fig. 3](#fig3){ref-type="fig"}), which together with subsequent data fitting using Hypspec and HySS,[@cit41],[@cit45] provided binding constants of log M(Aβ~1--16~) = 11.90 ± 0.01, and log M(Aβ~1--16~)(H) = 4.90 ± 0.02 (where M = **FeL1**, and (H) indicates a mono-protonated peptide species). This experiment demonstrates the much higher affinity of **FeL1** for the Aβ peptide in comparison to 1-MeIm (see below). At higher pH values (\>9.5) a metal hydrolysis species is evident (modelled as log M(Aβ~1--16~)(OH), presumably due to deprotonation of a bound H~2~O ligand). As indicated from the speciation diagram ([Fig. 3](#fig3){ref-type="fig"}), the interaction of **FeL1** with the Aβ peptide coincides with His deprotonation (reported p*K*~a~ values of 5.72, 6.5, and 6.95).[@cit46] Further analysis of the speciation diagram of **FeL1** with Aβ~1--16~ provides the binding affinity at physiological pH. The concentration of free **FeL1** present in solution at a given pH, referred to as pM (p(**FeL1**) = --log\[(**FeL1**)~unchelated~\]), is a direct estimate of metal--ligand affinity when all species in solution are considered.[@cit47] The calculated value for p(**FeL1**) is 6.6 (\[**FeL1**\] = \[Aβ~1--16~\] = 30 μM), which affords a *K*~d~ value of ∼10^--7^ M.[@cit18a],[@cit48] This value shows that the affinity of Aβ for **FeL1** is lower than for Cu([ii]{.smallcaps}) but larger than for Zn([ii]{.smallcaps}).

![(Top) variable pH UV-Vis titration of **FeL1** (30 μM) and Aβ~1--16~ (30 μM) from pH 3.1 (black) to pH 11.5 (blue). The red spectrum represents the maximum absorbance for the **FeL1**--Aβ complex at pH 8.2. (Bottom) using HypSpec and HySS,[@cit41] the variable pH data were fitted to a model including **FeL1**--Aβ, **FeL1**--Aβ(H), and a HO-**FeL1**--Aβ component at high pH. At pH 7.4 the majority of **FeL1** is bound to Aβ~1--16~ (\>99%).](c8sc04660c-f3){#fig3}

To gain more insight into the binding event, both ^1^H NMR and ESI-MS studies were performed. The MS spectrum of a 1 : 1 **FeL1** : Aβ~1--16~ adduct showed multiple *m*/*z* peaks consistent with **FeL1** binding to Aβ~1--16~, with the most intense adduct peak corresponding to \[**FeL1**--Aβ~1--16~\]^2+^ (Fig. S5[†](#fn1){ref-type="fn"}). **FeL1** has been reported to bind to human serum albumin (HSA),[@cit31] and in addition the Aβ peptide shows a specific interaction with HSA.[@cit49] Based on these reports we investigated the binding of **FeL1** to Aβ in the presence of HSA, and under these conditions observed the \[**FeL1**--Aβ~1--16~\]^2+^ adduct (Fig. S6[†](#fn1){ref-type="fn"}). The ^1^H NMR of Aβ~1--16~ was recorded in the presence of 0.10 and 0.25 equivalents of the paramagnetic **FeL1**.[@cit10b],[@cit50] Initially, the signals from the three histidines and the tyrosine were quite sharp and well resolved ([Fig. 4](#fig4){ref-type="fig"}, bottom trace). Addition of **FeL1** induced broadening of all signals attributed to the histidines (7.95, 7.05, 7.00 ppm), while those of Tyr^10^ (7.10 and 6.82 ppm) were not affected ([Fig. 4](#fig4){ref-type="fig"}, mid and top traces). Overall, the data are consistent with binding of an Aβ His residue to **FeL1**, and there is likely no preference for any of the available peptide His residues (His^6^, His^13^, His^14^).

![Changes in the ^1^H NMR spectra of Aβ~1--16~ in the presence of **FeL1**. Shown are spectra obtained at 210 μM Aβ~1--16~, in PBS buffer prepared in D~2~O pH 7.4 at 25 °C (red), with addition of 0.10 (green) and 0.25 equivalents (blue) of **FeL1**. \*His^6^, His^13^, and His^14^. ^†^Tyr^10^.](c8sc04660c-f4){#fig4}

**FeL1** binding to Aβ in the presence of Cu([ii]{.smallcaps})
--------------------------------------------------------------

### UV-Vis analysis

The affinity between Cu([ii]{.smallcaps}) and Aβ is very large (*K*~d~ of ∼10^--10^ M) and the inner coordination sphere of Cu([ii]{.smallcaps}) in the adduct is usually composed of the N-terminal amine, one carbonyl group and two histidines ([Scheme 2](#sch2){ref-type="fig"}, Component I, major species at pH = 7.4).[@cit10b],[@cit14a],[@cit38a],[@cit51] Although the affinity of **FeL1** to Aβ was found to be quite large (*K*~d~ ∼ 10^--7^ M) it is still 3 orders of magnitude lower than that of Cu([ii]{.smallcaps}), and thus is not expected to compete for the Cu([ii]{.smallcaps}) binding site. Considering, however, that the Aβ--Cu([ii]{.smallcaps}) adduct still has one His residue not involved in Cu binding, concurrent binding of Cu([ii]{.smallcaps}) and **FeL1** to Aβ is possible and of large potential interest. This aspect was addressed by combining **FeL1** with a preformed Aβ--Cu([ii]{.smallcaps}) complex and also *vice versa*, by adding Cu([ii]{.smallcaps}) to a **FeL1**/peptide mixture. Identical results were obtained in both cases ([Fig. 5](#fig5){ref-type="fig"} and S4[†](#fn1){ref-type="fn"}) and the corresponding UV-Vis spectra clearly revealed the earlier outlined spectral features associated with axial His binding. This shows that **FeL1** binds to the peptide even in the presence of Cu([ii]{.smallcaps}) and also provides another independent indication that the inner coordination sphere of **FeL1** has only one axial histidine ligand. The formation of the ternary adduct (1 : 1 : 1 **FeL1** : Aβ~1--16~ : Cu adduct) was further confirmed by ESI-MS, with *m*/*z* peaks corresponding to \[**FeL1**--Aβ--Cu([ii]{.smallcaps})\]^2+^ and sodium adducts (Fig. S5[†](#fn1){ref-type="fn"}).

![UV-Vis spectra of binding of **FeL1** (30 μM, black) in PBS buffer (0.01 M, pH 7.4) to 1 equiv. of Aβ~1--16~ with (blue) or without (green) Cu([ii]{.smallcaps}) (0.9 equiv.).](c8sc04660c-f5){#fig5}

### EPR characterization

In order to better understand the binding of both Cu([ii]{.smallcaps}) and **FeL1** to the Aβ peptide, we analyzed the electron paramagnetic resonance (EPR) spectra of Aβ~1--16~--Cu([ii]{.smallcaps}), **FeL1**--Aβ~1--16~, and finally **FeL1**--Aβ~1--16~--Cu([ii]{.smallcaps}). The EPR data for Aβ~1--16~--Cu([ii]{.smallcaps}) are in agreement with previous reports;[@cit12b],[@cit50],[@cit52] and simulation of the EPR spectra indicate the existence of both Component I and Component II therein ([Scheme 2](#sch2){ref-type="fig"} and Fig. S7[†](#fn1){ref-type="fn"}). The simulation parameters are detailed in [Table 1](#tab1){ref-type="table"}, and an approximate intensity ratio of 0.6 : 0.4 for Component I : Component II at pH 7.4 is in agreement with the measured p*K*~a~ value of 7.8 ± 0.5 ([Scheme 2](#sch2){ref-type="fig"}) *via* the Henderson--Hasselbalch equation.[@cit12b],[@cit50]

###### X-band EPR simulation parameters[^*a*^](#tab1fna){ref-type="fn"}

                                       Aβ--Cu([ii]{.smallcaps}) -- Component I   Aβ--Cu([ii]{.smallcaps}) -- Component II   **FeL1** (*S* = 3/2)   Fe bound (*S* = 1/2)                                                      
  ------------------------------------ ----------------------------------------- ------------------------------------------ ---------------------- ---------------------- ------ ------ ----- ----- ----- ----- ------ ----- -----
  Aβ--Cu([ii]{.smallcaps})             2.26                                      2.05                                       186                    0.6                    2.22   2.05   170   0.4   ---   ---   ---    ---   ---
  **FeL1**                             ---                                       ---                                        ---                    ---                    ---    ---    ---   ---   2.0   3.9   ---    ---   ---
  **FeL1** MeIm                        ---                                       ---                                        ---                    ---                    ---    ---    ---   ---   2.0   3.9   2.70   2.2   1.8
  **FeL1**--Aβ                         ---                                       ---                                        ---                    ---                    ---    ---    ---   ---   2.0   3.9   2.75   2.2   1.7
  **FeL1**--Aβ--Cu([ii]{.smallcaps})   2.26                                      2.05                                       186                    0.7                    2.22   2.05   170   0.3   2.0   3.9   2.75   2.2   1.7

^*a*^See experimental section for details.

^*b*^Component relative abundance.

**FeL1** in buffer displays a weak intermediate-spin Fe([iii]{.smallcaps}) signal at *g*~⊥~ = 3.9 and *g*~∥~ = 2.0,[@cit42b],[@cit53] whereas **FeL1**--Aβ~1--16~ shows, in addition to this signal, also a rhombic spin system consistent with low-spin Fe([iii]{.smallcaps}) ![](c8sc04660c-t1.jpg){#ugt1} species ([Table 1](#tab1){ref-type="table"} and Fig. S8[†](#fn1){ref-type="fn"}). The latter is similar to the spectrum for **FeL1** in the presence of 20 equiv. of 1-MeIm (Fig. S8[†](#fn1){ref-type="fn"}) and to reported EPR data for other 6-coordinate low spin Fe([iii]{.smallcaps}) corroles (with CN^--^ and pyridine as axial ligands).[@cit54] These data are consistent with contributions from both mono- and bis-axial ligated **FeL1** in the EPR experiment, likely due to the increased ligand affinity upon freezing the solutions for EPR analysis. Increased bis-axial ligation to **FeL1** is observed for both 1-MeIm and Aβ~1--16~ in solution at lower temperatures (10 °C) by UV-Vis (Fig. S10[†](#fn1){ref-type="fn"}), and freezing a 5-coordinate (OEC)Fe([iii]{.smallcaps})(py) corrole (OEC = trianion of 2,3,7,8,12,13,17,18-octaethylcorrole) in pyridine results in a similar spectral pattern with both intermediate and low spin signals.[@cit42b] Due to the distinct temperature-dependence of signal intensity for the EPR spectra of the Fe species it is not possible to accurately determine their ratios from these experiments.[@cit55]

Incubation of both Cu([ii]{.smallcaps}) and **FeL1** with Aβ~1--16~ affords the ternary species **FeL1**--Aβ~1--16~--Cu([ii]{.smallcaps}) with an EPR spectrum that is essentially the sum of the components Aβ~1--16~--Cu([ii]{.smallcaps}) and **FeL1**--Aβ~1--16~ ([Fig. 6](#fig6){ref-type="fig"}). The simulation parameters are detailed in [Table 1](#tab1){ref-type="table"}, with the two Cu([ii]{.smallcaps}) species Component I and Component II in a 0.7 : 0.3 ratio. While this differs slightly from the ratio for Aβ~1--16~--Cu([ii]{.smallcaps}) alone, the limited resolution of the spectra suggests minimal change to the Cu-site upon binding of **FeL1** to the peptide (*vide infra*). Similarly, the simulation parameters for the Fe species present in **FeL1**--Aβ~1--16~--Cu([ii]{.smallcaps}) ([Table 1](#tab1){ref-type="table"}) are identical to **FeL1**--Aβ~1--16~ suggesting that while both Cu([ii]{.smallcaps}) and **FeL1** bind to Aβ~1--16~, the binding sites are independent of one another as far as can be determined through the EPR experiments. This is reminiscent of reported EPR analysis of Cu([ii]{.smallcaps}) and heme with Aβ~1--16~, which also suggested that while both did bind to the peptide there was no observable interaction between the two metal centres.[@cit17a]

![Frozen-solution EPR spectrum (bottom), corresponding simulation (red) and spectral deconvolution of **FeL1** in the presence of 1 equiv. of both Aβ~1--16~ and Cu([ii]{.smallcaps}) at 20 K. (a) **FeL1**--Aβ component simulation (multiplied by a factor of 3), (b) Aβ--Cu([ii]{.smallcaps}) Component II simulation (c) Aβ--Cu([ii]{.smallcaps}) Component I simulation (d) sum of all simulated species and (e) experimental spectrum. Conditions: \[Aβ~1--16~\] = 550 μM, \[**FeL1**\] = \[Cu([ii]{.smallcaps})\] = 500 μM, in PBS buffer (0.05 M, pH 7.4). EPR parameters: frequency = 9.38 GHz, microwave power = 2.0 mW, time constant = 40.96 ms, modulation amplitude = 5G, average of five 1 min scans.](c8sc04660c-f6){#fig6}

Influence of **FeL1** on Aβ aggregation
---------------------------------------

Gel electrophoresis and western blotting, in combination with Transmission Electron Microscopy (TEM), were used to investigate if binding of **FeL1** to the Aβ peptide would alter the size distribution of Aβ species and the morphology of the resulting aggregates. The longer Aβ~1--42~ peptide was employed for this study, as it is most aggregation prone and neurotoxic.[@cit13b],[@cit56] Incubation with low concentrations of **FeL1** (0.1 to 1 equiv., for 24 h) significantly affected the aggregation pattern ([Fig. 7A](#fig7){ref-type="fig"}). While the Aβ~1--42~ peptide forms mostly high molecular weight aggregates (lane 1) in the absence of **FeL1**, consistent with previous reports,[@cit19a],[@cit24b],[@cit57] **FeL1** exhibits a concentration-dependent effect on the aggregation pattern (lanes 2--5). Only low molecular weight species were observed after 24 h with one equiv. of **FeL1** (lane 5). The influence of **FeL1** on Aβ~1--42~ aggregation was further confirmed by TEM ([Fig. 7B--D](#fig7){ref-type="fig"}). The TEM image for peptide alone shows long fibrils and large aggregate size, matching previous reports.[@cit24b],[@cit57] However, as the concentration of **FeL1** is increased, a reduction in aggregate size is observed, with only small aggregates present with 1 equiv. of **FeL1** ([Fig. 7D](#fig7){ref-type="fig"}). We also investigated the effect of the free ligand **L1** on Aβ~1--42~ peptide aggregation. Under the same experimental conditions, **L1** also displays a concentration-dependent effect on aggregation (Fig. S11[†](#fn1){ref-type="fn"}), however aggregate species are observed over a broad molecular weight range. We hypothesize that **L1** alters the aggregation pattern *via* hydrophobic interactions with the Aβ peptide,[@cit19a],[@cit37],[@cit58] while the covalent interaction of **FeL1** with Aβ His residues results in the preferential formation of low molecular weight species ([Fig. 7](#fig7){ref-type="fig"}).

![Influence of **FeL1** on the aggregation profile of Aβ~1--42~. (A) Gel electrophoresis/Western blot of 25 μM Aβ~1--42~ and different concentrations of **FeL1** in PBS buffer (0.01 M, pH 7.4) after 24 h incubation with agitation at 37 °C, using anti-Aβ antibody 6E10. Lane 1: Aβ~1--42~; lane 2: Aβ~1--42~ + **FeL1** (0.1 equiv.); lane 3: Aβ~1--42~ + **FeL1** (0.25 equiv.); lane 4: Aβ~1--42~ + **FeL1** (0.5 equiv.); lane 5: Aβ~1--42~ + **FeL1** (1 equiv.). And TEM images of (B) Aβ~1--42~; (C) Aβ~1--42~ + 0.1 equiv. **FeL1**; and (D) Aβ~1--42~ + 1 eq **FeL1**.](c8sc04660c-f7){#fig7}

Catalytic antioxidant activity
------------------------------

**FeL1** has been previously reported to exhibit exceptional antioxidant activity for the disproportionation of H~2~O~2~,[@cit30d] dismutation of O~2~˙^--^,[@cit30a] and catalytic activity for the decomposition of peroxynitrite (PN, ONOO^--^).[@cit32] In addition, the antioxidant activity of **FeL1** is maintained, and even enhanced, when bound to albumin, lipoproteins, or imidazole since this minimizes formation of the less catalytically-active μ-oxo iron([iv]{.smallcaps}) dimer.[@cit30c],[@cit30d] This work highlighted that the **FeL1**--Aβ species could act as a potent antioxidant, and possibly minimize ROS generation from Aβ--Cu([ii]{.smallcaps}) when both **FeL1** and Cu([ii]{.smallcaps}) are bound to the peptide simultaneously.

### Catalase activity

The catalase activity of **FeL1** has been demonstrated to exceed that of any other synthetic mimic of the enzyme,[@cit30d],[@cit31],[@cit59] and its activity increases in the presence of excess imidazole. In order to determine the influence of **FeL1** binding to Aβ~1--16~ on its catalase activity, an "Amplex Red"/H~2~O~2~ catalase assay was performed. This assay relies on competing with the very fast color producing reaction by adding a complex that catalytically decomposes H~2~O~2~. A catalase standard curve (Fig. S12A[†](#fn1){ref-type="fn"}) was prepared and different concentrations of **FeL1** in the presence and absence of Aβ~1--16~ (Fig. S12B[†](#fn1){ref-type="fn"}) were tested to determine their activity. Both **FeL1** and the 1 : 1 **FeL1**--Aβ~1--16~ adduct displayed good catalase activity, with the latter being superior. This shows that His binding of the Aβ peptide to **FeL1** results in an enhancement of catalase activity at all concentrations studied (1--5 μM).

### Aβ--Cu([ii]{.smallcaps}) ROS production

Under biologically relevant reducing conditions, which are commonly mimicked by reducing agents such as ascorbate (Asc), Aβ--Cu([ii]{.smallcaps}) species are known to produce an array of ROS composed of superoxide anion radical, hydrogen peroxide, and hydroxyl radical.[@cit38b],[@cit51] There are many protocols for investigating the multiple steps that lead to these damaging species ([Scheme 3](#sch3){ref-type="fig"}), of which the first one is the oxidation of Asc by Cu([ii]{.smallcaps}). This process was followed by monitoring the time course for disappearance of the Asc absorption band at 265 nm ([Fig. 8](#fig8){ref-type="fig"}) in the presence of CuCl~2~ and **FeL1** only, their binary adducts with Aβ~1--16~, and the ternary adduct formed by combining Aβ~1--16~ with Cu([ii]{.smallcaps}) and **FeL1**. Consistent with previous reports,[@cit51] the high rate of Asc consumption in the presence of Cu([ii]{.smallcaps}) is diminished when bound to Aβ~1--16~; and consistent with expectations, both **FeL1** and **FeL1**--Aβ did not promote Asc oxidation. The most revealing result is that the ternary **FeL1**--Aβ~1--16~--Cu([ii]{.smallcaps}) complex displayed only slightly enhanced Asc oxidation in comparison to Aβ~1--16~--Cu([ii]{.smallcaps}) only. Overall, and in accordance with the EPR results that show that **FeL1** does not alter the Cu([ii]{.smallcaps}) binding site, this assay suggests that the presence of **FeL1** does not significantly affect the reduction of Aβ--Cu([ii]{.smallcaps}) by Asc.

![Reactive oxygen species generated by Aβ--Cu([ii]{.smallcaps}) in the presence of ascorbate and the possible assays to detect them, modified from C. Cheignon *et al.* 2018.[@cit38b]](c8sc04660c-s3){#sch3}

![Ascorbate consumption by Cu([ii]{.smallcaps}) (black), Aβ--Cu([ii]{.smallcaps}) (blue); **FeL1**--Aβ--Cu([ii]{.smallcaps}) (red); **FeL1**--Aβ (purple); **FeL1** (green), measured using UV-Vis spectroscopy (*λ* = 265 nm) as a function of time in PBS buffer (0.01 M, pH 7.4). \[Asc\] = 100 μM, \[Aβ~1--16~\] = \[**FeL1**\] = 10 μM and \[CuCl~2~\] = 9 μM.](c8sc04660c-f8){#fig8}

Cu--Aβ species can transform O~2~ to H~2~O~2~ through a series of steps, which can be detected *via* its reaction with Amplex Red, which forms the intensively colored resorufin ([Scheme 3](#sch3){ref-type="fig"}).[@cit60] Following this process by monitoring the formation of resorufin ([Fig. 9A](#fig9){ref-type="fig"}) revealed that: (a) Cu([ii]{.smallcaps}) alone induces the fastest rate of formation of H~2~O~2~; (b) the binding of Cu([ii]{.smallcaps}) to Aβ slows down the process, as reported previously;[@cit61] and (c) the ternary **FeL1**--Aβ~1--16~--Cu([ii]{.smallcaps}) species shows a reduced rate of H~2~O~2~ formation and lower amount overall. The latter phenomenon is consistent with **FeL1** quenching the H~2~O~2~ that is produced by the bound Cu([ii]{.smallcaps}), due to the good catalase-like activity of **FeL1** in both its free form and when bound to the Aβ peptide (Fig. S12B[†](#fn1){ref-type="fn"}). In addition to catalase activity, **FeL1** displays exceptional antioxidant activity for the dismutation of O~2~˙^--^,[@cit30a] and thus the complex may also quench superoxide formed as shown in [Scheme 3](#sch3){ref-type="fig"}. Detection of this reactivity using a cytochrome c assay[@cit9b],[@cit17b] was challenging due to interference of **FeL1** absorption bands.

![ROS production by Aβ--Cu([ii]{.smallcaps}) in the presence of ascorbate. (A) Amplex red assay for H~2~O~2~ formation by UV-Vis absorbance at 570 nm. \[Asc\] = 400 μM, \[Aβ~1--16~\] = \[**FeL1**\] = \[Cu([ii]{.smallcaps})\] = 20 μM, \[Amplex red\] = 100 μM; \[HRP\] = 0.4 U mL^--1^ (where 1 unit is defined as the amount of enzyme that will form 1.0 mg purpurogallin from pyrogallol in 20 seconds at pH 6.0 at 20 °C). (B) CCA assay for ·OH formation measured by fluorescence, *λ*~ex~ 395 nm and *λ*~em~ 450 nm. \[Asc\] = 300 μM, \[Aβ~1--16~\] = \[**FeL1**\] = \[Cu([ii]{.smallcaps})\] = 40 μM, \[CCA\] = 100 μM. ![](c8sc04660c-u1.jpg){#ugr1} Cu([ii]{.smallcaps}); ![](c8sc04660c-u2.jpg){#ugr2} Aβ--Cu([ii]{.smallcaps}); ![](c8sc04660c-u3.jpg){#ugr3} **FeL1**--Aβ--Cu([ii]{.smallcaps}); ![](c8sc04660c-u4.jpg){#ugr4} **FeL1**--Aβ; ![](c8sc04660c-u5.jpg){#ugr5} **FeL1**.](c8sc04660c-f9){#fig9}

The last and most damaging step in [Scheme 3](#sch3){ref-type="fig"} occurs *via* the formation of the hydroxyl radical (·OH) from the reaction of Cu([i]{.smallcaps}) with H~2~O~2~ ([Scheme 3](#sch3){ref-type="fig"}), which may be detected by the reaction of 3-coumarin carboxylic acid (3-CCA) with ·OH to form the fluorescent 7-hydroxy-3-coumarin-carboxylic acid (7-OH-3-CCA).[@cit62] Consistent with previous reports,[@cit12e] ·OH production is quite fast and significant for Aβ--Cu([ii]{.smallcaps}) albeit much less than for non-His-coordinated Cu([ii]{.smallcaps}) ([Fig. 9B](#fig9){ref-type="fig"}). The addition of **FeL1**, to form the ternary **FeL1**--Aβ~1--16~--Cu([ii]{.smallcaps}) species, resulted in a further 6-fold reduction in the amount of 7-OH-3-CCA. In principle, this may reflect either the lower availability of H~2~O~2~ due to the catalase-like activity or the direct quenching of ·OH by **FeL1**, or a combination of both. Another possible interpretation is that Cu in the ternary complex is less reactive, which is unlikely considering the minimal interaction of **FeL1** with Aβ~1--16~--Cu([ii]{.smallcaps}) binding motif. In any case, the almost complete elimination of hydroxyl radical formation demonstrates that the potent antioxidant activity of **FeL1** is maintained when bound to the Aβ peptide.

Summary
=======

This study underlines the ability of **FeL1** to target both Aβ peptide aggregation and ROS formation, two factors influencing AD progression. **FeL1** and the free corrole ligand **L1** influence Aβ aggregation differently; **FeL1** stabilizes low molecular weight species while **L1** stabilizes aggregates over a broad MW range. **FeL1** forms a 1 : 1 adduct with Aβ *via* axial binding of one His residue with a moderate binding affinity (*K*~d~ of ∼ 10^--7^ M), which is weaker in comparison to Cu binding to Aβ (*K*~d~ of ∼ 10^--10^ M) but still stronger than Zn([ii]{.smallcaps}) binding (*K*~d~ of ∼10^--5^ M).[@cit10b],[@cit14a],[@cit38a],[@cit51] It is interesting to note that **FeL1** has a much higher affinity for Aβ peptide His residues than 1-MeIm or free His, suggesting significant non-covalent interactions between **FeL1** and the Aβ peptide. These results are in agreement with the specific binding of **FeL1** to HDL2 proteins in comparison to other serum constituents, due to the amphipolar character of **FeL1**.[@cit30c] Indeed, **L1** was also shown to influence Aβ peptide aggregation likely due to hydrophobic interactions, albeit to a significantly lower extent. In a similar manner, non-covalent π--π stacking interactions, in addition to covalent binding, have been shown to dictate the association of Pt([ii]{.smallcaps})(phenanthroline) complexes with the Aβ peptide.[@cit21a],[@cit29],[@cit63]

We have also shown herein that **FeL1** binds to the Aβ peptide concurrently with Cu([ii]{.smallcaps}). Our EPR data suggests no significant change in the Cu-binding site with **FeL1** His coordination. This is further corroborated by the ascorbate oxidation assay, which displays only minor changes to the rate of ascorbate oxidation for Aβ--Cu([ii]{.smallcaps}) and the ternary species **FeL1**--Aβ--Cu([ii]{.smallcaps}). However, the bound **FeL1** acts as an efficient catalase, and decomposes a significant fraction of the H~2~O~2~ generated by Aβ--Cu([ii]{.smallcaps}) ([Fig. 9A](#fig9){ref-type="fig"}). In the presence of **FeL1** we also observe a decrease in the formation of ·OH ([Fig. 9B](#fig9){ref-type="fig"}), consistent with the result from the amplex red assay. Our results show that amphipolar **FeL1** binds specifically to the Aβ peptide *via* a His residue in a 1 : 1 stoichiometry, and this interaction modulates the peptide aggregation pathway. In addition, the peptide-bound **FeL1** maintains its exceptional antioxidant activity, limiting ROS formation from Aβ--Cu([ii]{.smallcaps}). Overall, our results highlight the promising multifunctional character of **FeL1** to limit Aβ peptide aggregation and the formation of damaging ROS, two hallmarks of AD.

Conflicts of interest
=====================

There are no conflicts to declare.

Supplementary Material
======================

Supplementary information

###### 

Click here for additional data file.

This work was supported by Natural Sciences and Engineering Research Council (NSERC) Discovery Grant (T. S., M. A. S., and C. J. W.), a Michael Smith Career Investigator Award (T. S.), and a New Investigator Grant from the Alzheimer\'s Association (NIRG-15-362537), Brain Canada (to T. S.) and Science without borders (CAPES -- Proc. no. 0711/13-6, Brazil to L. M. F. G.). Dr Andrew Lewis is thanked for assistance with NMR measurements. K. E. P. acknowledges a NSERC Vanier CGS for support. Z. G. and A. M. acknowledge The Israel Science Foundation for support.

[^1]: †Electronic supplementary information (ESI) available. See DOI: [10.1039/c8sc04660c](10.1039/c8sc04660c)
